This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should Value Investors Buy Humana (HUM) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
UnitedHealth Group (UNH) Expands Home Healthcare Business
by Zacks Equity Research
UnitedHealth Group (UNH) boosts home healthcare presence with the acquisition of Amedisys for $3.3 billion
UnitedHealth's (UNH) Optum Rx Makes Patient Care Affordable
by Zacks Equity Research
UnitedHealth Group, Inc's. (UNH) Optum Rx is set to offer three biosimilar alternatives for HUMIRA effective Jul 1, providing affordability in patient care.
Profiting from the 3rd Wave of the App Economy
by Andrew Rocco
The third wave of the application economy will be driven by the onset of VR headsets and Artificial Intelligence. Because of their partnerships with tech juggernauts, two companies stand to benefit the most.
Humana's (HUM) CenterWell Unit Plans to Expand in Tennessee
by Zacks Equity Research
Humana's (HUM) CenterWell business is likely to benefit from its promising plans to expand across middle Tennessee this year.
Here's Why Buying Brookdale (BKD) Stock is a Prudent Move Now
by Zacks Equity Research
For the second quarter, Brookdale (BKD) expects RevPAR growth to be in the range of 11.5-12%.
Here's Why Hold Strategy is Apt for The Joint (JYNT) Stock Now
by Zacks Equity Research
The Joint (JYNT) is expected to keep growing due to rising patient visits and new clinic openings.
The Joint (JYNT) Buys Wisconsin Regional Developer Zone Rights
by Zacks Equity Research
The Joint (JYNT) expects the Wisconsin region to hold a total of 53 clinics, of which 21 are currently operating.
U.S. Health Insurers Are Tumbling: Should You be Worried?
by Kaibalya Pravo Dey
Demand for procedures like hip and knee surgeries is rising, which will leave fewer premiums in hand after paying for the procedures for the health insurers.
Humana (HUM) Sees Insurance Costs at Upper Limit of Guidance
by Zacks Equity Research
Despite the rising demand for elective procedures, Humana (HUM) sticks to its earnings guidance.
Humana (HUM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $463.85, marking a +1.95% move from the previous day.
UnitedHealth (UNH) Falls 6.4% on Cost Woes of Resumed Surgeries
by Zacks Equity Research
UnitedHealth's (UNH) Optum Health unit is likely to witness higher utilization, especially in ambulatory surgery operations.
Humana (HUM) Wins Contract to Serve Oklahoma's Medicaid Members
by Zacks Equity Research
Humana (HUM) secures a contract from the OHCA and is likely to provide improved health outcomes for Medicaid members of Oklahoma.
Humana (HUM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Humana (HUM) closed at $513.34 in the latest trading session, marking a +0.69% move from the prior day.
Zacks Industry Outlook Highlights UnitedHealth Group, The Cigna Group, Humana, Centene Corporation and Molina Healthcare
by Zacks Equity Research
UnitedHealth Group, The Cigna Group, Humana, Centene Corporation and Molina Healthcare are part of the Zacks Industry Outlook article.
Humana (HUM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Humana (HUM) closed the most recent trading day at $509.83, moving +1.02% from the previous trading session.
5 HMO Industry Stocks to Watch as Technology Expenses Take a Toll
by Debasmita Chatterjee
The Medical-HMO industry is witnessing growth in customer base and an active M&A strategy. However, high technology expenses and medical personnel shortage raise concerns. UNH, CI, HUM, CNC and MOH are likely to navigate the industry storms.
Humana (HUM) Arm Reaches 250 Senior Primary Care Facilities
by Zacks Equity Research
Humana's (HUM) CenterWell business focuses on providing a better healthcare experience through clubbing primary care, home health and pharmacy services.
Humana (HUM) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Humana (HUM) closed at $520.78 in the latest trading session, marking a +1.09% move from the prior day.
CI or HUM: Which HMO Stock is Better Placed at the Moment?
by Zacks Equity Research
Cigna (CI) and Humana (HUM) are well-positioned to expand in the promising HMO space. Let's try to find out which one fares better via comparative evaluation.
Humana (HUM) Down 4.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Humana (HUM) in Your Portfolio
by Zacks Equity Research
Humana (HUM) remains well-poised for growth, attributable to a growing customer base, numerous contract wins and solid cash-generating abilities.
Humana (HUM) Teams Up With DME Entities to Boost Home Solutions
by Zacks Equity Research
These partnerships will equip Humana (HUM) with the means to deploy advanced clinical programs that can reduce hospitalizations for the members.
Here's Why Humana (HUM) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Select Medical (SEM) Q1 Earnings Top on Improving Profitability
by Zacks Equity Research
Select Medical (SEM) expects revenues to be within the range of $6.5-$6.7 billion in 2023, indicating a rise of 4.8% from the 2022 figure of $6.3 billion.